Share on StockTwits

BioMed Realty Trust (NYSE:BMR) CEO Alan D. Gold unloaded 26,615 shares of the stock in a transaction dated Wednesday, August 13th. The stock was sold at an average price of $22.17, for a total transaction of $590,054.55. Following the sale, the chief executive officer now directly owns 432,562 shares in the company, valued at approximately $9,589,900. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

BMR has been the subject of a number of recent research reports. Analysts at Stifel Nicolaus reiterated a “buy” rating on shares of BioMed Realty Trust in a research note on Monday, August 11th. They now have a $24.00 price target on the stock, up previously from $23.00. Separately, analysts at Jefferies Group raised their price target on shares of BioMed Realty Trust from $23.00 to $25.00 in a research note on Tuesday, July 22nd. Finally, analysts at MLV & Co
initiated coverage on shares of BioMed Realty Trust in a research note on Friday, June 27th. They set a “hold” rating and a $23.00 price target on the stock. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. BioMed Realty Trust currently has an average rating of “Buy” and a consensus price target of $23.29.

BioMed Realty Trust (NYSE:BMR) opened at 22.18 on Monday. BioMed Realty Trust has a 52-week low of $17.90 and a 52-week high of $22.47. The stock’s 50-day moving average is $21.8 and its 200-day moving average is $21.03. The company has a market cap of $4.236 billion and a price-to-earnings ratio of 83.70.

BioMed Realty Trust (NYSE:BMR) last announced its earnings results on Tuesday, August 5th. The company reported $0.40 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.36 by $0.04. The company had revenue of $171.16 million for the quarter, compared to the consensus estimate of $160.80 million. During the same quarter in the prior year, the company posted $0.37 earnings per share. The company’s quarterly revenue was up 7.2% on a year-over-year basis. On average, analysts predict that BioMed Realty Trust will post $1.53 earnings per share for the current fiscal year.

BioMed Realty Trust, Inc operates as a real estate investment trust (NYSE:BMR), and the general partner of BioMed Realty, L.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.